COSM · Cosmos Health Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the date of this filing.”View the 10-Q filed May 20, 2026
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$3,361,385 | FY 2025 | — |
| Adjusted Net Income (Loss) per Share non-GAAP | -$0.12 | FY 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Distribution — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COSM
this stock
Cosmos Health Inc.
|
$10.61M | -63.3% | +19.9% | — | 10.3% |
|
MCK
Mckesson Corp
|
$106.81B | +8.4% | +3.1% | 23.2 | 3.2% |
|
COR
Cencora, Inc.
|
$62.18B | -5.5% | +9.3% | 24.5 | 3.0% |
|
CAH
Cardinal Health Inc
|
$54.71B | +12.0% | -1.9% | — | 2.9% |
|
HSIC
Henry Schein Inc
|
$9.76B | +13.6% | +5.9% | 25.9 | 5.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COSM | -14.1% | -1.1% | -60.9% | -1.1% | -63.3% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -11.7% | +1.2% | -67.2% | +1.2% | -70.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.